Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.
about
Modeling HIV-1 Induced Neuroinflammation in Mice: Role of Platelets in Mediating Blood-Brain Barrier DysfunctionPrevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy.Comparative study on infection-induced thrombocytopenia among returned travellers.Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects.HIV and SIV Associated Thrombocytopenia: An Expanding Role for Platelets in the Pathogenesis of HIV.Platelet count kinetics following interruption of antiretroviral treatment.Thrombocytopenia in HIV-Infected PatientsTGFβ-Mediated Downregulation of Thrombopoietin Is Associated With Platelet Decline in Asymptomatic SIV InfectionInitial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.Prevalence of thrombocytopenia among Chinese adult antiretroviral-naïve HIV-positive patients.Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia.HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologiesThe association of HIV viral load with indirect markers of liver injury.Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.Haematological manifestations of human immune deficiency virus infection.Prevalence of thrombocytopenia before and after initiation of HAART among HIV infected patients at black lion specialized hospital, Addis Ababa, Ethiopia: a cross sectional study.
P2860
Q28550869-CF33BA5B-6D0B-4D5B-8248-8904205D6B20Q33395500-402290C3-33AA-4D4A-901D-9871AC78DA62Q33399831-A01649E8-7C21-4729-9C19-2832EF18495EQ33400092-CFA244FB-4ADB-4B55-BCF9-9F25C1F024AAQ33401168-E0B43D90-6417-401E-B3C3-20D8A278FE8BQ33403565-1698656F-6B75-442A-9163-648E189ABC27Q33408152-105D49E7-B313-43F1-913E-9DC14507DCC0Q33411414-0BF6EB30-743C-49FE-9C37-3D77563320FAQ33419335-B923F318-C2A9-431A-BF01-32916783EFF3Q33420327-05B393ED-D650-48AF-A789-4F36CDBA0D2EQ33427012-B785FE05-80F8-46DD-8CA4-CD8503DB4900Q34561257-EC81FFA8-295D-43F9-9100-6C78913C37C1Q35681714-54C51376-B2CE-4A63-AC11-E92371E3CFC6Q36799939-E63E8DF6-157C-4D7F-84BD-DD7C6FCB77FAQ38603109-F4AF03AC-075D-4ADC-B0D3-8FC233770A5AQ53682131-111EFEE9-4663-4891-823C-E5B2EA56697B
P2860
Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Risk factors for thrombocytope ...... potent antiretroviral therapy.
@ast
Risk factors for thrombocytope ...... potent antiretroviral therapy.
@en
type
label
Risk factors for thrombocytope ...... potent antiretroviral therapy.
@ast
Risk factors for thrombocytope ...... potent antiretroviral therapy.
@en
prefLabel
Risk factors for thrombocytope ...... potent antiretroviral therapy.
@ast
Risk factors for thrombocytope ...... potent antiretroviral therapy.
@en
P2093
P2860
P1476
Risk factors for thrombocytope ...... potent antiretroviral therapy.
@en
P2093
Andrew H Talal
Kristen M Marks
Marshall J Glesby
Robin M A Clarke
P2860
P304
P356
10.1097/QAI.0B013E3181B79AFF
P407
P577
2009-12-01T00:00:00Z